What are the presentation, diagnostic work‑up, and management for acute and chronic mesenteric ischemia in adult patients, especially those with risk factors such as atrial fibrillation, recent myocardial infarction, heart failure, hypercoagulable states, or atherosclerosis?

Mesenteric Ischemia: Presentation, Diagnosis, and Management

Clinical Presentation

Acute mesenteric ischemia presents with severe periumbilical abdominal pain that is classically "out of proportion to physical examination findings" in the absence of peritoneal signs, particularly in patients with atrial fibrillation, recent myocardial infarction, or other thromboembolic risk factors. 1

Acute Mesenteric Ischemia (AMI)

• Patient demographics: Approximately two-thirds are women with a median age of 70 years, and most have pre-existing cardiovascular disease 1
• Embolic disease (50% of AMI cases): Atrial fibrillation is present in nearly 50% of embolic cases; other major risk factors include recent myocardial infarction, cardiac thrombi, mitral valve disease, left ventricular aneurysm, and previous embolic disease 2, 1
• Arterial thrombosis: Occurs in patients with severe atherosclerotic disease 2
• Mesenteric venous thrombosis: Affects younger patients with hypercoagulable states 3
• Non-occlusive mesenteric ischemia (NOMI): Associated with hypotension, shock, and low cardiac output states 2

Chronic Mesenteric Ischemia (CMI)

• Classic triad: Post-prandial abdominal pain, food fear, and weight loss 1, 4
• Underlying pathology: Associated with diffuse atherosclerotic disease in >95% of cases, typically involving stenosis or occlusion of at least two of the three major mesenteric vessels (celiac artery, superior mesenteric artery, inferior mesenteric artery) 5, 4
• Presentation is indolent: Diagnosis is frequently delayed because CMI is rare and symptoms overlap with many common causes of abdominal pain and weight loss 1

Diagnostic Work-Up

Acute Mesenteric Ischemia

Contrast-enhanced CT angiography (CTA) of the abdomen and pelvis should be obtained immediately in all cases of suspected acute mesenteric ischemia, as it is the gold standard with 95-100% sensitivity and specificity. 1

• Triple-phase CTA protocol: Perform non-contrast, arterial, and portal venous phases to simultaneously evaluate mesenteric vasculature and assess bowel viability 2
• Critical pitfall to avoid: Do NOT delay CTA due to elevated creatinine—the mortality risk of missing AMI far outweighs the risk of contrast-induced nephropathy 1
• CTA findings in embolic disease: Occlusive filling defect in the proximal superior mesenteric artery (SMA), typically 3-10 cm distal to its origin, classically sparing the proximal jejunum and colon 2
• Ischemic bowel changes on CTA: Thickened, edematous, dilated small bowel with variable enhancement surrounded by free fluid; look for pneumatosis intestinalis or portal venous gas indicating advanced disease 2

Laboratory tests: Elevated lactate and leukocytosis may support the diagnosis, but normal values should NOT be used to exclude mesenteric ischemia 6

Conventional angiography: Provides superior anatomic detail for NOMI diagnosis and enables immediate therapeutic intervention 7

Chronic Mesenteric Ischemia

• Initial imaging options: Duplex ultrasound, CTA, or gadolinium-enhanced MRA all have approximately 90% accuracy 1
• CTA is preferred: Provides comprehensive evaluation of all three mesenteric vessels and degree of stenosis 4
• Diagnostic criteria: Requires both appropriate clinical symptoms AND significant mesenteric artery occlusive disease, particularly involving the superior mesenteric artery 4

Management

Initial Resuscitation for All Types (Before Definitive Treatment)

• Immediate fluid resuscitation to enhance visceral perfusion 7
• Broad-spectrum antibiotics to prevent infection 2, 7
• Intravenous unfractionated heparin unless contraindicated, to prevent thrombosis recurrence 7
• Nasogastric decompression to reduce aspiration risk and improve intestinal perfusion 7
• Correction of electrolyte abnormalities 7

Acute Arterial Occlusive Disease (Embolic or Thrombotic)

For patients WITHOUT peritoneal signs, pursue endovascular therapy first (aspiration embolectomy, thrombolysis, or angioplasty with stenting), as this approach is associated with decreased bowel resection, lower rates of renal/respiratory failure, lower incidence of short bowel syndrome, and reduced mortality compared to primary surgical approaches. 2, 7

• Endovascular success rates: Technical success up to 94% with contemporary techniques 2
• Aspiration embolectomy: One retrospective study of 8 patients showed 100% survival at 12 months when combined with anticoagulation 2
• Transcatheter thrombolysis: May be added if significant distal thrombus burden is present 7
• Catheter-directed vasodilators: May benefit patients with associated vasospasm 7

For patients WITH peritoneal signs, proceed directly to urgent laparotomy with bowel resection as needed—endovascular therapy is contraindicated when bowel infarction is present. 7

Critical caveat: Despite endovascular-first approach, up to 70% of patients may still require surgical intervention for bowel resection and/or diversion 2

Non-Occlusive Mesenteric Ischemia (NOMI)

Primary treatment focuses on correcting the underlying cause (optimize cardiac output, eliminate vasopressors) and improving mesenteric perfusion with vasodilator therapy. 7

• Intra-arterial papaverine: Traditional first-line vasodilator administered via catheter 7
• Alternative vasodilators: Intra-arterial nitroglycerin, intra-arterial glucagon, or high-dose intravenous prostaglandin E1 (may be equally effective) 7
• Surgical intervention: Only if bowel infarction is present 7

Mesenteric Venous Thrombosis

• Primary treatment: Continuous infusion of unfractionated heparin 2, 7
• Supportive measures: Nasogastric suction, fluid resuscitation, and bowel rest 7
• Surgical intervention: Only required if bowel infarction occurs 7

Chronic Mesenteric Ischemia

Endovascular therapy with percutaneous transluminal angioplasty and stent placement is the preferred initial treatment, having largely replaced open surgical repair due to lower mortality and morbidity. 1, 7, 4

• Stent selection: Balloon-expandable covered stents are preferred for ostial lesions due to superior precision and higher radial force; covered stents show lower restenosis rates (10% vs. 50%) compared to bare-metal stents 7
• Technical success: 85-100% with stent placement 7
• Endovascular outcomes: Significantly lower postoperative mortality (OR 0.20,95% CI 0.17-0.24) and shorter hospital stays compared to open surgery 7
• Limitations: Higher rates of restenosis, recurrent symptoms, and need for reintervention compared to open repair 1, 7
• Long-term survival: 1-year and 3-year survival estimates after endovascular repair are 85% and 74%, respectively 7

Open surgical revascularization should be considered for failed endovascular therapy, extensive occlusion, severe calcifications, or technical difficulties precluding endovascular access; it offers superior long-term patency and lower reintervention rates 7

Critical treatment principle: Do NOT delay revascularization to improve nutritional status—this approach has been associated with clinical deterioration, bowel infarction, and sepsis 7

Prophylactic revascularization in asymptomatic patients is NOT recommended, even when significant stenosis is detected on imaging 7

Surgical Considerations for Acute Mesenteric Ischemia

• Damage control surgery: Use temporary abdominal closure for patients requiring intestinal resection 7
• Mandatory second-look procedures: Required in patients with extensive bowel involvement to reassess viability 7
• Delay anastomosis: Until bowel viability is confirmed 7

Postoperative and Long-Term Management

• Intensive care: Directed toward improving intestinal perfusion and preventing multiple organ failure 7
• Continued anticoagulation: Necessary to prevent thrombosis recurrence 7
• Lifelong antiplatelet therapy: Indicated following treatment of chronic mesenteric ischemia 7
• Best medical therapy: Implement statin therapy, blood pressure control, diabetes management, and lifestyle modifications 7

Critical Pitfalls to Avoid

• Maintain high clinical suspicion in elderly patients with cardiovascular disease and severe abdominal pain—this is a Class I recommendation 1
• Do NOT use normal lactate or laboratory values to exclude the diagnosis 6
• Do NOT delay CTA for elevated creatinine 1
• Do NOT treat single-vessel disease in isolation—occlusive disease of only one mesenteric artery makes CMI unlikely; search for alternative diagnoses 7
• Do NOT use systemic nitrates (e.g., ISMN)—there is no evidence supporting their use, and they could worsen mesenteric perfusion by causing hypotension without targeted mesenteric vasodilation 7

Prognosis

• Acute mesenteric ischemia mortality: Remains 40-70% despite advances in diagnosis and treatment; approaches 60% with delayed diagnosis 2, 7
• Mortality exceeds 50% without prompt revascularization 7
• In cases of massive gut necrosis: Carefully assess the patient's comorbidities and advanced directives to guide treatment decisions 7